A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United ...

They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...